Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Institutional

3 ICM researchers won a Sanofi Innovation Award

Published on: 30/05/2018 Reading time: 4 min
Visual Sanofi Innovation Award

Violetta Zujovic, Olga Corti and Stéphane Hunot, researchers at Institut du Cerveau - ICM, obtained an important grant from the Sanofi Innovation Awards (iAwards) programme for their research.

The Sanofi Innovation Awards (iAwards) program supports the development of early stage innovative and translational research projects which could lead to effective and safer therapeutic solutions for patients in different pathologies. Then, the idea is to to convert successful projects to sponsored research programs and subsequently create in-licensing and start-up opportunities.

This year, 3 Institut du Cerveau - ICM researchers have obtained this important support for their projects: Violetta Zujovic, Olga Corti, and Stéphane Hunot.

The projects

COMPuting and ASSessing biological networks in Multiple Sclerosis patients macrophages - COMPASS in MS (Violetta Zujovic)

Multiple sclerosis (MS) is an autoimmune disease, which is characterized by inflammation in the central nervous system and demyelination, leading to axonal degeneration. While demyelinated axons can be remyelinated through an endogenous process, this capacity varies greatly between patients. Since macrophages contribute to demyelination but also orchestrate remyelination, we aim to identify potential intrinsic defects in macrophages’ response to pro-inflammatory and -regenerative signals to determine if this contributes to remyelination failure.

Combining transcriptomic, functionality of MS patient macrophages and patient’s clinical data through multivariate analyses and network-generating algorithms, we plan to define the dysregulated genes and the potential targets that can correct the network. Our ambition is to develop powerful mathematical tools, enabling to reprogram “in silico” specific biological networks in order to maximize macrophage activation towards a “patient specific” regenerative phenotype.

Targeting inflammasome overactivation in Parkinson's disease (Olga Corti and Jean-Christophe Corvol)

Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder involving several pathogenic mechanisms, including neuroinflammation and mitochondrial dysfunction. There is significant clinical and pathophysiological heterogeneity among PD patients. Stratification according to physiopathological profiles based on meaningful biomarkers is key to the development of new clinical trials and therapeutic solutions adapted to each patient.

The PD-linked gene PARK2/Parkin plays a pivotal role in the regulation of mitochondrial quality control and has emerged as a key regulator of innate immune responses. Recent work by the team demonstrated that Parkin deficiency is associated with NRLP3 inflammasome overactivation. This defect is caused by deregulation of a major negative feedback loop mediated by a specific target that restricts inflammasome activity. It has been previously shown that this target is expressed at detectable levels in the blood.

The project of the team led by Olga Corti and Jean-Christophe Corvol aims to validate the newly identified target involved in NLRP3 inflammasome restriction as potential biomarker for stratifying subgroups of PD patients with a neuroinflammatory profile. This approach will provide an entry point towards personalized treatment targeting the NRLP3 inflammasome in PD. Once validated, the target may serve as a companion biomarker to assess of the therapeutic efficacy of drugs targeting the inflammasome.

Identification and validation of targets and markers of Parkinson's disease-associated neuroinflammation (Stéphane Hunot)

Among the mechanisms occurring in PD, misfolding and aggregation of alpha-synuclein is thought to play an important role in neurodegeneration. However, the correlation between synucleinopathy and neuronal death in PD brain is rather weak. Therefore, cellular context and non-cell autonomous mechanisms may also play a critical role.

In PD, mounting evidence suggests that α-Syn assemblies could be central to microglial cell activation and pathological inflammatory responses. Microglia cells perform a number of physiological functions important for the maintenance of tissue homeostasis. Yet, chronic stimulation causes microglial cells to get activated and generate an immune response potentially harmful for neurons. It is crucial to define and understand the mechanisms that shape microglial cell polarization to design tools to therapeutically modulate this response in a beneficial orientation.

The overall objective of Stéphane Hunot and his team is to identify and validate molecular targets and functions linked to microglial cell activation under PD-specific stimulatory and inflammatory conditions. To reach this goal, they will develop a cellular model of PD- and chronic-type inflammation, conduct unbiased analysis of molecular changes through multimodal omics approach by combining transcriptomics (RNAseq) and metabolomics and eventually validate the most robust markers in patient-derived biological material.

Our news on the subject

Visuel Voeux 2025
2025: An ambitious dynamic led by Prof. Stéphanie DEBETTE, the new Executive Director of the Institute since January 1, 2025
Professor Gérard SAILLANT, President of Paris Brain Institute, extends his warmest wishes to all those who, by faithfully supporting the research carried out at the institute, enable us to make a tangible difference in our fight against brain...
01.08.2025 Institutional
Stéphanie Debette
Professor Stéphanie Debette takes the helm of Paris Brain Institute
Appointed Executive Director of Paris Brain Institute for a five-year term, Professor Stéphanie Debette took up her new position on January 1, 2025. She succeeds Professor Alexis Brice, who has served as Executive Director since 2012.
01.07.2025 Institutional
L'IRM 7 Tesla à l’Institut du Cerveau
A 7-Tesla MRI scanner at Paris Brain Institute: cutting-edge technology at the service of scientific ambition
This week, Paris Brain Institute inaugurated an exceptional piece of equipment: the latest generation 7-Tesla MAGNETOM Terra.X MRI scanner from Siemens Healthineers. This acquisition, made possible thanks to the support of RICHARD MILLE and the...
11.28.2024 Institutional
Les participants du Dîner annuel de Paris Brain Institute America
Annual Dinner of Paris Brain Institute America at the French Consulate in New York – A Resounding Success for Neuroscience Research
On October 8, 2024, the French Consulate in New York hosted the annual dinner of Paris Brain Institute America (PBIA), gathering prominent philanthropists and influential figures from the scientific community for an evening dedicated to transatlantic...
10.15.2024 Support
erc
Nikolas Karalis, team leader at the Paris Brain Institute, is awarded the ERC Starting Grant 2024.
The European Research Council's (ERC) Starting Grants are prestigious and highly competitive awards, designed to enable young scientists to build their research team, and to carry out ambitious and innovative projects addressing unexplored scientific...
09.16.2024 Institutional
L'une des présentation lors de la visite
A special international visit: members and friends of the International Olympic Committee discover Paris Brain Institute
On Wednesday July 31, the Institute had the pleasure of welcoming a special group of visitors: members of the International Olympic Committee (IOC) and their friends and families.
09.08.2024 Institutional
See all our news